 Karen Christopher
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract Extraction | 10 | 2025 | 97 | 5.400 |
Why?
| | Cataract | 11 | 2023 | 208 | 5.270 |
Why?
| | Keratomileusis, Laser In Situ | 4 | 2024 | 22 | 2.970 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 43 | 2.950 |
Why?
| | Myopia | 5 | 2024 | 47 | 2.940 |
Why?
| | Refraction, Ocular | 5 | 2024 | 36 | 2.580 |
Why?
| | Visual Acuity | 8 | 2024 | 326 | 2.480 |
Why?
| | Lasers, Excimer | 4 | 2024 | 29 | 2.400 |
Why?
| | Phacoemulsification | 6 | 2025 | 116 | 2.300 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 19 | 1.660 |
Why?
| | Retinal Detachment | 2 | 2023 | 58 | 1.510 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 9 | 1.490 |
Why?
| | Diabetic Retinopathy | 2 | 2023 | 179 | 1.370 |
Why?
| | Intraoperative Complications | 4 | 2024 | 129 | 1.350 |
Why?
| | Blood Loss, Surgical | 2 | 2020 | 96 | 1.120 |
Why?
| | Ophthalmology | 2 | 2023 | 82 | 0.950 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.890 |
Why?
| | Optics and Photonics | 2 | 2021 | 43 | 0.860 |
Why?
| | Descemet Stripping Endothelial Keratoplasty | 1 | 2022 | 7 | 0.810 |
Why?
| | Endothelium, Corneal | 1 | 2022 | 16 | 0.810 |
Why?
| | Retinal Perforations | 1 | 2022 | 13 | 0.760 |
Why?
| | Postoperative Complications | 6 | 2024 | 2481 | 0.760 |
Why?
| | Lens Implantation, Intraocular | 4 | 2022 | 59 | 0.720 |
Why?
| | Lens Subluxation | 1 | 2021 | 3 | 0.710 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 5 | 0.710 |
Why?
| | Corneal Stroma | 1 | 2020 | 17 | 0.700 |
Why?
| | Corneal Neovascularization | 1 | 2020 | 15 | 0.700 |
Why?
| | Keratitis | 1 | 2020 | 14 | 0.690 |
Why?
| | Eye Infections, Bacterial | 1 | 2020 | 27 | 0.680 |
Why?
| | Endophthalmitis | 1 | 2020 | 28 | 0.680 |
Why?
| | Retrospective Studies | 15 | 2024 | 14553 | 0.670 |
Why?
| | Hepatitis C | 1 | 2022 | 244 | 0.650 |
Why?
| | Vitreous Body | 1 | 2020 | 109 | 0.650 |
Why?
| | Scurvy | 1 | 2019 | 14 | 0.620 |
Why?
| | Heroin Dependence | 1 | 2019 | 31 | 0.600 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2444 | 0.590 |
Why?
| | Follow-Up Studies | 8 | 2024 | 4896 | 0.560 |
Why?
| | Conjunctival Neoplasms | 1 | 2017 | 7 | 0.550 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 12 | 0.550 |
Why?
| | Fingolimod Hydrochloride | 1 | 2017 | 39 | 0.540 |
Why?
| | Conjunctiva | 1 | 2017 | 51 | 0.530 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 73 | 0.510 |
Why?
| | Anterior Chamber | 1 | 2015 | 22 | 0.490 |
Why?
| | Internship and Residency | 2 | 2025 | 1058 | 0.450 |
Why?
| | Bacteria | 1 | 2020 | 814 | 0.440 |
Why?
| | Cytoprotection | 1 | 2013 | 56 | 0.430 |
Why?
| | Humans | 32 | 2025 | 129847 | 0.430 |
Why?
| | alpha-Crystallin B Chain | 1 | 2013 | 24 | 0.420 |
Why?
| | Thrombocytopenia | 1 | 2015 | 189 | 0.420 |
Why?
| | Aged, 80 and over | 8 | 2024 | 7066 | 0.420 |
Why?
| | Crystallins | 1 | 2013 | 59 | 0.410 |
Why?
| | Lens, Crystalline | 1 | 2013 | 123 | 0.380 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 31 | 0.370 |
Why?
| | Hot Temperature | 1 | 2013 | 369 | 0.360 |
Why?
| | Artificial Intelligence | 2 | 2025 | 245 | 0.360 |
Why?
| | Cornea | 2 | 2022 | 128 | 0.350 |
Why?
| | Aged | 10 | 2024 | 22107 | 0.300 |
Why?
| | Academic Medical Centers | 2 | 2022 | 483 | 0.300 |
Why?
| | Male | 16 | 2025 | 63759 | 0.290 |
Why?
| | Oxidative Stress | 1 | 2013 | 1264 | 0.270 |
Why?
| | Clinical Competence | 2 | 2025 | 1020 | 0.270 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3630 | 0.260 |
Why?
| | Middle Aged | 9 | 2024 | 31177 | 0.250 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.230 |
Why?
| | Axial Length, Eye | 1 | 2024 | 15 | 0.220 |
Why?
| | Refractive Errors | 1 | 2024 | 18 | 0.220 |
Why?
| | Female | 12 | 2024 | 68829 | 0.220 |
Why?
| | Ophthalmologists | 1 | 2023 | 12 | 0.210 |
Why?
| | Language | 2 | 2023 | 283 | 0.210 |
Why?
| | Descemet Membrane | 1 | 2022 | 5 | 0.200 |
Why?
| | Wet Macular Degeneration | 1 | 2023 | 45 | 0.200 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 218 | 0.200 |
Why?
| | Geographic Atrophy | 1 | 2023 | 68 | 0.200 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 81 | 0.200 |
Why?
| | Tissue and Organ Harvesting | 1 | 2022 | 70 | 0.190 |
Why?
| | Cell Count | 1 | 2022 | 318 | 0.190 |
Why?
| | Alanine Transaminase | 1 | 2022 | 154 | 0.190 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.180 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.180 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.180 |
Why?
| | Treatment Outcome | 4 | 2024 | 10241 | 0.180 |
Why?
| | Microscopy | 1 | 2022 | 140 | 0.180 |
Why?
| | Proportional Hazards Models | 1 | 2024 | 1199 | 0.180 |
Why?
| | Weapons | 1 | 2021 | 8 | 0.180 |
Why?
| | Civil Disorders | 1 | 2021 | 7 | 0.180 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.180 |
Why?
| | Intraoperative Period | 1 | 2020 | 55 | 0.180 |
Why?
| | Hepacivirus | 1 | 2022 | 242 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Biometry | 1 | 2021 | 69 | 0.170 |
Why?
| | Eye Injuries | 1 | 2021 | 46 | 0.170 |
Why?
| | Dementia | 1 | 2023 | 227 | 0.170 |
Why?
| | Vitrectomy | 1 | 2020 | 66 | 0.170 |
Why?
| | Health Status Disparities | 1 | 2023 | 256 | 0.170 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 10 | 0.170 |
Why?
| | Tattooing | 1 | 2020 | 14 | 0.160 |
Why?
| | Survival Rate | 1 | 2024 | 1872 | 0.160 |
Why?
| | Tissue Donors | 1 | 2022 | 391 | 0.160 |
Why?
| | Laser Therapy | 1 | 2021 | 129 | 0.160 |
Why?
| | Retinal Diseases | 1 | 2020 | 87 | 0.160 |
Why?
| | HIV | 1 | 2020 | 227 | 0.160 |
Why?
| | Risk Factors | 2 | 2024 | 9801 | 0.160 |
Why?
| | United States | 5 | 2023 | 13913 | 0.160 |
Why?
| | Macular Edema | 1 | 2020 | 43 | 0.160 |
Why?
| | Arthritis, Reactive | 1 | 2019 | 8 | 0.160 |
Why?
| | Education, Medical, Graduate | 1 | 2023 | 443 | 0.150 |
Why?
| | Postoperative Period | 1 | 2020 | 330 | 0.150 |
Why?
| | Uveitis | 1 | 2020 | 127 | 0.150 |
Why?
| | Prosthesis Design | 1 | 2020 | 309 | 0.140 |
Why?
| | Metformin | 1 | 2021 | 316 | 0.140 |
Why?
| | Biopsy | 2 | 2020 | 1089 | 0.140 |
Why?
| | Healthcare Disparities | 1 | 2023 | 580 | 0.130 |
Why?
| | Ultrasonography | 1 | 2020 | 713 | 0.130 |
Why?
| | Curriculum | 1 | 2023 | 928 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1434 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2022 | 3384 | 0.110 |
Why?
| | Adult | 6 | 2020 | 35634 | 0.110 |
Why?
| | Aldehyde Reductase | 1 | 2013 | 28 | 0.110 |
Why?
| | Cell-Penetrating Peptides | 1 | 2013 | 21 | 0.110 |
Why?
| | Protein Structure, Quaternary | 1 | 2013 | 121 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 858 | 0.100 |
Why?
| | Cell Death | 1 | 2013 | 353 | 0.100 |
Why?
| | Cell Survival | 1 | 2013 | 1086 | 0.080 |
Why?
| | Recombinant Proteins | 1 | 2013 | 1311 | 0.080 |
Why?
| | Anti-Bacterial Agents | 1 | 2020 | 1708 | 0.080 |
Why?
| | Vascular Endothelial Growth Factor A | 2 | 2023 | 528 | 0.080 |
Why?
| | Cell Line | 1 | 2013 | 2780 | 0.070 |
Why?
| | Oxygen Inhalation Therapy | 1 | 1987 | 145 | 0.060 |
Why?
| | Intubation, Intratracheal | 1 | 1987 | 248 | 0.060 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2008 | 254 | 0.060 |
Why?
| | Video Recording | 1 | 2025 | 164 | 0.060 |
Why?
| | Safety-net Providers | 1 | 2023 | 110 | 0.050 |
Why?
| | Dissent and Disputes | 1 | 2021 | 17 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 35 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 56 | 0.040 |
Why?
| | Adalimumab | 1 | 2020 | 40 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 27 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 158 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 509 | 0.040 |
Why?
| | Health Surveys | 1 | 2021 | 495 | 0.040 |
Why?
| | Software | 1 | 2023 | 608 | 0.040 |
Why?
| | Mutation | 1 | 2008 | 3706 | 0.030 |
Why?
| | Colorado | 1 | 2023 | 4410 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1221 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2023 | 5085 | 0.020 |
Why?
| | Time Factors | 1 | 2021 | 6550 | 0.020 |
Why?
| | TRPP Cation Channels | 1 | 2008 | 79 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1987 | 176 | 0.020 |
Why?
| | Rest | 1 | 1987 | 120 | 0.020 |
Why?
| | Physical Exertion | 1 | 1987 | 210 | 0.020 |
Why?
| | Genetic Testing | 1 | 2008 | 422 | 0.020 |
Why?
| | Hypoxia | 1 | 1987 | 1087 | 0.010 |
Why?
| | Young Adult | 1 | 2008 | 12467 | 0.010 |
Why?
|
|
Christopher's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|